Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
Status:
NOT_YET_RECRUITING
Trial end date:
2030-04-01
Target enrollment:
Participant gender:
Summary
The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including those with and without clonal hematopoiesis driven by mutations in TET2.
Phase:
PHASE2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Broad Institute of MIT and Harvard National Institutes of Health (NIH) Yale University